Eli Lilly strikes $2.75 billion deal with Insilico Medicine to accelerate AI drug development
13 Sources
[1]
Lilly, Insilico Ink Deal on AI Drugs Worth Up to $2.75 Billion
Eli Lilly & Co. has signed an AI-powered drug development deal with Insilico Medicine that could be worth up to $2.75 billion. Under the deal, announced Sunday, Insilico is eligible for $115 million in upfront payments; other milestones could bring the value to $2.75 billion, plus tiered royalties
[2]
Eli Lilly to sign $2 billion deal for AI drug development with Hong Kong's Insilico Medicine, FT says
March 29 (Reuters) - Eli Lilly (LLY.N), opens new tab will sign a $2 billion deal with Hong Kong-listed biotech Insilico Medicine (3696.HK), opens new tab, which uses artificial intelligence for drug discovery, the Financial Times reported on Sunday. Lilly will acquire exclusive rights to sell a
[3]
Eli Lilly to sign $2bn deal for AI drug development with Hong Kong biotech
US drugmaker Eli Lilly will sign a $2bn deal with a Hong Kong-listed company that uses artificial intelligence for drug discovery, according to sources familiar with the matter, highlighting the global pharmaceutical sector's increasing reliance on medicines developed in China. Indianapolis-based
[4]
Eli Lilly reaches $2.75 billion deal with Insilico to bring AI-developed drugs to the global market
BEIJING -- U.S. pharmaceutical giant Eli Lilly has reached a $2.75 billion deal to bring drugs developed using artificial intelligence by Hong Kong-based Insilico Medicine to the global market. The agreement will give Insilico $115 million up front, with the remainder subject to regulatory and
[5]
Eli Lilly bets on AI-powered drugs in new deal with Insilico Medicine
Eli Lilly has partnered with AI biotech Insilico Medicine for exclusive global rights to develop and commercialise medicines designed entirely by artificial intelligence. Eli Lilly and Insilico Medicine have struck a new deal on AI-driven drug discovery, the companies announced on Sunday. Under
[6]
Pharma Giant Eli Lilly Is Paying $2.75 Billion for Drugs Designed by AI - Here's What It Gets Them
Eli Lilly is betting big that generative AI can do more than just write code and create images. It can design cures for diseases. The pharma giant just reached a $2.75 billion deal with Hong Kong-based Insilico Medicine to bring AI-discovered drugs to market, reports CNBC. Insilico gets $115
[7]
Eli Lilly to sign $2 billion deal for AI drug development with Hong Kong's Insilico Medicine: Report
Lilly will acquire exclusive rights to sell a GLP-1 drug for diabetes from Insilico Medicine, the FT report said, citing sources familiar with the matter. Eli Lilly will sign a $2 billion deal with Hong Kong-listed biotech Insilico Medicine , which uses artificial intelligence for drug
[8]
Eli Lilly Strikes $2.75B Deal To Bring AI-Developed Drugs Globally - Eli Lilly (NYSE:LLY)
Eli Lilly & Co. (NYSE:LLY) has reportedly finalized a $2.75 billion agreement to introduce AI-developed drugs from Hong Kong's Insilico Medicine to the global market. Details Of The Deal The collaboration between the two firms began with an AI-based software licensing deal in 2023. Andrew Adams,
[9]
Lilly and Novo Show How AI Is Rewiring Big Pharma | PYMNTS.com
By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions. Eli Lilly signed a $2.75 billion partnership with Hong Kong-based AI drug
[10]
Eli Lilly Makes $2.75 Billion Bet on AI-Powered Drug Discovery | PYMNTS.com
To that end, the company has struck a $2.75 billion deal, announced Sunday (March 29), with Hong Kong-based Insilico Medicine. The companies say this collaboration will use Insilico's artificial intelligence (AI) engine to accelerate the "discovery and development of novel therapeutics." The
[11]
Eli Lilly signs $2.75 billion drug discovery deal with InSilico By Investing.com
Investing.com -- Eli Lilly (NYSE:LLY) signed a drug discovery agreement with Hong Kong-listed InSilico that could reach a total value of $2.75 billion, the companies announced Sunday. Under the terms of the agreement, InSilico will receive an upfront payment of $115 million. The company is
[12]
InSilico, Lilly ink AI drug discovery deal worth up to $2.75 billion By Investing.com
Investing.com - InSilico Medicine Cayman TopCo (HK:3696) announced a global licensing and AI-driven drug discovery collaboration with Eli Lilly and Company (NYSE:LLY), in a deal that could be worth up to $2.75 billion, according to a company filing. Under the agreement, Lilly will receive
[13]
Eli Lilly Strikes AI Drug Discovery Deal With InSilico Worth Up to $2.75 Billion -- Update
Eli Lilly signed a drug discovery deal with InSilico that the Hong Kong-listed company says could be valued at as much as $2.75 billion, as global pharmaceutical giants continue to tap China's drug development pipeline. Under the agreement announced Sunday, InSilico will receive an upfront payment
Share
Copy Link
Eli Lilly has signed a major partnership with Hong Kong-based Insilico Medicine worth up to $2.75 billion to develop AI-powered drugs. The deal includes $115 million upfront and gives Lilly exclusive global rights to commercialize therapeutics designed by artificial intelligence. Insilico has already developed 28 drugs using generative AI, with nearly half in clinical stages.
Eli Lilly Expands AI Drug Development with Major Insilico Medicine Partnership
Eli Lilly has signed a landmark agreement with Insilico Medicine that could reach $2.75 billion, marking one of the pharmaceutical industry's most significant bets on AI drug development
1
. The deal gives Eli Lilly exclusive rights to develop and commercialize AI-powered drugs designed by the Hong Kong-based biotechnology firm, with Insilico Medicine receiving $115 million in upfront payment3
. Additional milestone payments tied to regulatory approvals and commercial success could bring the total value to $2.75 billion, plus tiered royalties on future sales5
.
Source: PYMNTS
The partnership builds on an existing collaboration between the two companies dating back to 2023, when they first signed an AI-based software licensing agreement
4
. Under the new arrangement, Lilly will collaborate on multiple research and discovery programs for specific targets chosen by the pharmaceutical giant, though the companies did not specify which disease areas they're pursuing1
. According to sources familiar with the matter, the deal includes exclusive rights to a GLP-1 drug for diabetes, positioning Lilly to expand its already dominant presence in metabolic disease treatment2
.Accelerate Drug Discovery Through Advanced AI Platforms
Insilico Medicine has emerged as a leader in AI-driven biotechnology, developing at least 28 drugs using generative AI tools, with nearly half already at clinical stages, according to founder and CEO Alex Zhavoronkov
4
. The company's Pharma.AI platform integrates biology, chemistry, and clinical analysis to identify novel disease targets and design new drug molecules5
. Founded in 2014 at Johns Hopkins University in Baltimore, Insilico was an early pioneer in developing drugs with artificial intelligence before the current AI boom3
.Andrew Adams, group vice president of molecule discovery at Eli Lilly, emphasized that "Insilico's AI-enabled discovery capabilities represent a powerful complement to Lilly's deep expertise in clinical development across multiple therapeutic areas"
5
. The partnership aims to accelerate drug discovery by exploring novel mechanisms and identifying promising therapeutic candidates more rapidly than traditional methods allow. As part of the agreement, Insilico will join Lilly's Gateway Labs community for biotechnology development4
.Related Stories
Lilly's Strategic Push Beyond Obesity Drugs
Despite unprecedented success with obesity drugs like Mounjaro, which became the world's second-biggest drug by sales in 2025, Eli Lilly is investing heavily in AI to build its next generation of medicines
3
. The company has constructed an Nvidia-powered supercomputer at its Indianapolis headquarters and announced plans in January to create a new $1 billion research lab in San Francisco1
. CEO Dave Ricks articulated the urgency at an event with Nvidia CEO Jensen Huang, stating: "The challenge before us now is how would we find another success cycle before that one runs out, hopefully a lot sooner than it runs out, and sort of get exit velocity. Can we find more biology using AI? That is really the Holy Grail"1
.
Source: Euronews
The pharmaceutical industry's embrace of AI drug development carries significant risks alongside its promise. In its February annual report, Lilly added new language warning that "there are significant risks involved in developing and deploying AI," noting it cannot guarantee its AI investments will prove effective or profitable
3
. The company also acknowledged that "AI may enable new competitors in drug discovery and enhance the capabilities of existing competitors, thereby broadening and intensifying competitive dynamics"3
. Speaking at a March conference, Lilly CFO Lucas Montarce noted the company is investing heavily in AI for research and development but cautioned that "it will take more time" to move AI drugs from research to clinical testing3
. This timeline challenge matters for investors watching Lilly's stock, which has declined 17% in 2026 amid new competition from Novo Nordisk's weight-loss pill3
. The Insilico partnership represents a calculated bet that AI can compress the typically arduous drug discovery process and deliver the next wave of blockbuster treatments before current revenue streams plateau.References
Summarized by
Navi
[4]
Related Stories
Eli Lilly and Nvidia Partner to Build Pharmaceutical Industry's Most Powerful AI Supercomputer for Drug Discovery
29 Oct 2025•Health
Eli Lilly Launches $1 Billion AI-Powered Drug Discovery Platform
09 Sept 2025•Technology
Eli Lilly Invests $409M in AI-Driven Drug Discovery Partnership with Genetic Leap
06 Sept 2024
Recent Highlights
1
OpenAI's AI Math Breakthrough on Navier-Stokes Equations Sparks Major Attribution Controversy
Science and Research
2
Anthropic Researcher Quits, Warns Self-Improving AI Poses Existential Risk to Humanity
Policy and Regulation
3
Nvidia CEO Jensen Huang Declares AGI Has Arrived With OpenAI's GPT-6 Astra Release
Technology
Recent Highlights
Today's Top Stories
Don’t drown in AI news. We cut through the noise - filtering, ranking and summarizing the most important AI news, breakthroughs and research daily. Follow topics that matter to you and stay ahead.
